Luminex Corp. (Austin, TX) and BD Diagnostics-TriPath (Franklin Lakes, NJ), have announced a development and supply agreement, under which BD Diagnostics-TriPath will develop, market, and sell new biomarker-based diagnostic tests for certain cancers using Luminex's multiplexing xMAP technology platform.
Cohera Medical Inc. (Pittsburgh) has secured $16.1 million in a Series B financing for the ongoing development of TissuGlu, a novel surgical adhesive for sprayable application in plastic surgery. The financing was led by Bradford Capital Partners and included participation from existing investors led by Kern Whelan Capital LLC.
Privately held T2 Biosystems Inc. (Cambridge, MA) has raised $10.8 million in a Series B financing that will accelerate the development of the first portable medical diagnostic products that combine nanotechnology and miniaturized magnetic resonance technology. The company's initial investors, Flagship Ventures, Polaris Venture Partners, and Flybridge Capital Partners were joined by new investors Partners Healthcare and In-Q-Tel. T2